IONS vs NVST
Ionis Pharmaceuticals, Inc. vs Envista Holdings — AI-powered side-by-side comparison
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
VS
NVST
Envista Holdings
76
Strong Buy
| Metric | IONS | NVST |
|---|
| AI Score |
43
|
76
|
| Price |
$55.38
|
$28.51
|
| P/E Ratio |
-16.02×
|
48.34×
|
| ROE |
-77.9%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.2%
|
55.5%
|
| Debt / Equity |
5.50×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
46.6
|
59.3
|
| Beta |
0.4
|
0.861
|
| Expected Upside |
—
|
+1.4%
|
AI Committee View
Current Innellis committee reasoning for IONS versus NVST.
NVST leads by 33 points.
NVST scores 76/100 (Strong Buy) versus IONS at 43/100 (Reduce).
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.